Reaction SMILES: [CH3:1][CH:2]([C:4]1[CH:9]=[CH:8][C:7]2[C:10]3([CH3:21])[CH:15]([CH2:16][CH2:17][C:6]=2[CH:5]=1)[C:14]([CH2:19][NH2:20])([CH3:18])[CH2:13][CH2:12][CH2:11]3)[CH3:3].C[CH:23]([C:25]1[CH2:38][CH2:37][C@H:36]2[C:27](=CC[C@@H]3[C@]2(C)CCC[C@]3(CN)C)[CH:26]=1)C.CC(C1CC[C@H]2C(=CC[C@@H]3[C@]2(C)CCC[C@]3(CO)C)C=1)C.C[C@]1(CO)C2[C@@](C)(C3C(=CC2)C=C(C(C)C)CC3)CCC1.C[C@]1(CN)C2[C@@](C)(C3C(=CC2)C=C(C(C)C)CC3)CCC1.C[C@]1(C(N)=O)C2[C@@](C)(C3C(=CC2)C=C(C(C)C)CC3)CCC1.CNC([C@@]1(C)C2[C@@](C)(C3C(=CC2)C=C(C(C)C)CC3)CCC1)=O.C[C@]1(CNC)C2[C@@](C)(C3C(=CC2)C=C(C(C)C)CC3)CCC1.C(N(CC)C([C@@]1(C)C2[C@@](C)(C3C(=CC2)C=C(C(C)C)CC3)CCC1)=O)C.C[C@]1(CN(CC)CC)C2[C@@](C)(C3C(=CC2)C=C(C(C)C)CC3)CCC1.CC(C1C=CC2C3(C)C(CCC=2C=1)C(CN)(C)CCC3)C.C[C@]1(CN)C2[C@@](C)(C3C(CC2)=CC(C(C)C)=CC=3)CCC1.C[C@]1(CNC(=O)C)C2[C@@](C)(C3C(CC2)=CC(C(C)C)=CC=3)CCC1.C[C@]1(CNC(=O)C(F)(F)F)C2[C@@](C)(C3C(CC2)=CC(C(C)C)=CC=3)CCC1.C[C@]1(CNC(=O)C(Br)(Br)Br)C2[C@@](C)(C3C(CC2)=CC(C(C)C)=CC=3)CCC1.C(C1C=C2C([C@]3(C)C(CC2)[C@@](CNC(=O)C2C=CC=CC=2)(C)CCC3)=CC=1)(C)C>>[CH2:23]([NH:20][CH2:19][C@@:14]1([CH3:18])[CH:15]2[C@@:10]([CH3:21])([C:7]3[C:6]([CH2:17][CH2:16]2)=[CH:5][C:4]([CH:2]([CH3:1])[CH3:3])=[CH:9][CH:8]=3)[CH2:11][CH2:12][CH2:13]1)[C:25]1[CH:38]=[CH:37][CH:36]=[CH:27][CH:26]=1
Reactant: CC(C)C1=CC2=CC[C@H]3[C@](C)(CN)CCC[C@]3(C)[C@H]2CC1
Reactant: CC(C)c1ccc2c(c1)CCC1C(C)(CN)CCCC21C
Agent: CC(=O)NC[C@]1(C)CCC[C@]2(C)c3ccc(C(C)C)cc3CCC12
Agent: CC(C)C1=CC2=CCC3[C@](C)(CCC[C@@]3(C)C(N)=O)C2CC1
Agent: CC(C)C1=CC2=CCC3[C@](C)(CN)CCC[C@]3(C)C2CC1
Product: CC(C)c1ccc2c(c1)CCC1[C@](C)(CNCc3ccccc3)CCC[C@]21C

Procedure:
Anti-cancer pharmaceutical liposome compositions including one or more anti-cancer compositions selected from the group consisting of: leelamine, abietylamine, abietyl alcohol/GPR-8/[(1R,4aR)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthren-1-yl]methanol; abietylamine/GPR-3/{[(1R,4aR)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthren-1-yl]methyl}amine; abieticamide/GPR-2/(1R,4aR)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxamide; N-methylabieticamide/GPR-6/(1R,4aR)—N,1,4a-trimethyl-7-(propan-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxamide; N-methylabietylamine/GPR-7/{[(1R,4aR)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthren-1-yl]methyl}(methyl)amine; N,N-diethylabieticamide/GPR-11/(1R,4aR)—N,N-diethyl-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxamide; N,N-diethylabietylamine/GPR-12/{[(1R,4aR)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthren-1-yl]methyl}diethylamine; leelamine/[(1R,4aS)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl]methanamine; N-acetylleelamine/GPR-4L/N-{[(1R,4aS)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl]methyl}acetamide; N-trifluoroacetylleelamine/GPR-1L/N-{[(1R,4aS)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl]methyl}-2,2,2-trifluoroacetamide; N-tribromoacetylleelamine/GPR-5L/N-{[(1R,4aS)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl]methyl}-2,2,2-tribromoacetamide; N-benzoylleelamine/GPR-7L/N-(((1R,4aS)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl)methyl)benzamide; and N-benzylleelamine/GPR-8L/N-benzyl-1-((1R,4aS)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl)methanamine, are provided according to aspects of the present invention.